YSB Inc.
China's largest pharmaceutical digital service platform. Committed to using digitalization to empower participants.
China's largest pharmaceutical digital service platform. Committed to using digitalization to empower participants.
Yaoshibang is a B2B pharmaceutical trading platform that was founded in 2015. The company recently received a significant $270.00M Series E investment on 15 June 2021. The investors in this round included Green Pine Capital Partners, Baidu, SFUND, and Pearl River Investment. This impressive investment underscores the confidence that leading investment firms have in Yaoshibang's potential within the pharmaceutical trading industry. The company's ability to attract such high-profile investors speaks to the strength and promise of its business model and market positioning within this sector.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series E | $270.00M | 4 |
|
15 Jun 2021 |
| Series D | $133.00M | 3 |
|
17 Dec 2018 |
| Series C | CNY420.00M | 3 |
|
14 Jun 2018 |
| Series B | CNY110.00M | - | 08 Feb 2017 | |
| Series A | CNY71.00M | - | 05 Apr 2016 |
No recent news or press coverage available for YSB Inc..
We care about your data, and we'd love to use cookies make your experience better.
